Ehave, Inc., (OTC Pink: EHVVF), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, announced today that it received confirmation from the U.S. Food and Drug Administration (“FDA”) that its review of Ehave’s Investigational New Drug (“IND”) application is complete. The FDA authorized Ehave to proceed with its clinical study, “An…

Ehave, Inc., (OTC Pink: EHVVF), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, today issued a letter to shareholders from its Chief Executive Officer, Ben Kaplan. Dear Fellow Shareholders As 2022 draws to a close, many of us will reflect on a year that saw global economic activity experiencing a…

Ehave, Inc. (OTC Pink: EHVVF), a leading healthcare services and technology company, reaffirms its commitment to shareholders to launch its KetaDASH brand by completing the purchase of 100% of Rejuv IV. Rejuv IV provides mobile IV therapy in the San Francisco Bay Area, 7 days a week with flexible scheduling. Rejuv IV provides Ketamine treatments, as well…

Ehave, Inc. announced today the company is ahead of schedule and plans launch its KetaDASH (www.ketadash.com) ketamine IV therapy by the end of the second quarter.